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Background: Cirrhosis is a long-term consequence of chronic hepatic injury with fibrosis. No effective therapy is
currently available for decompensated cirrhosis except liver transplantation. Hence, we investigated the effect of
bone marrow-derived mesenchymal stem cells (BM-MSCs) on hepatic fibrosis in a thioacetamide (TAA)-induced
cirrhotic rat model.
Methods: The BM-MSCs were injected directly into the right liver lobe twice, at 6 and 8 weeks during the
12-week TAA administration, in thioacetamide (TAA)-induced cirrhotic rats model, and hepatic fibrosis was
evaluated. At 12 weeks, the effect of BM-MSCs on hepatic fibrosis was analyzed histomorphologically using the
Laennec fibrosis scoring system, and the collagen proportionate area was quantified. Cirrhosis-related factors,
such as transforming growth factor β1 (TGF-β1), type 1 collagen (collagen-1), α-smooth muscle actin (α-SMA),
and P-Smad3/Smad3 expression levels, were evaluated using real-time polymerase chain reaction and western
blot assays.
Results: According to the Laennec fibrosis scoring system, histological improvement was observed in hepatic
fibrosis after BM-MSC treatment (P <0.01). The percentage of the collagen proportionate area decreased from
16.72 ± 5.51 to 5.06 ± 1.27 after BM-MSC treatment (P <0.01). The content of hepatic hydroxyproline was significantly
lower in the BM-MSC treated group (46.25 ± 13.19) compared to the untreated cirrhotic group (85.81 ± 17.62; P <0.01).
BM-MSC administration significantly decreased TGF-β1, collagen-1, and α-SMA expression in TAA-induced cirrhotic rats
(P <0.01). We also confirmed P-Smad3/Smad3, downstream effectors of the TGF-β1 signaling pathway, and found
that MSC transplantation inhibited Smad3 phosphorylation.
Conclusions: BM-MSC treatment attenuated hepatic fibrosis in rats with TAA-induced cirrhosis, raising the possibility
of the clinical use of BM-MSCs in the treatment of cirrhosis.
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Cirrhosis, the end stage of progressive hepatic fibrosis, is
characterized by distortion of the hepatic architecture
and the formation of regenerative nodules, angiogenesis,
and shunts, leading to loss of liver function and the devel-
opment of hepatocellular carcinoma [1-6]. The most ef-
fective therapy for advanced cirrhosis is currently liver
transplantation. However, this procedure has several* Correspondence: baiksk@yonsei.ac.kr
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unless otherwise stated.limitations, including a lack of donors, surgical complica-
tions, immunological suppression, and a high medical cost
[7]; thus, there is a need for a new therapeutic paradigm
in this field.
Cell-based therapy, such as hepatocyte transplantation,
has been considered a potential alternative to liver trans-
plantation. Alternative therapeutic approaches that cir-
cumvent the use of the whole organ, such as the
transplantation of cells of various origins, have recently
been accepted [8,9]. In addition, stem cell transplantation
has been suggested as an effective alternate therapy for
hepatic disease [10,11]. Several previous studies usingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bone marrow (BM) cell transplantation may accelerate the
liver regeneration process, reduce hepatic fibrosis, and im-
prove liver function and survival [12-15]. The prospects
for stem cell transplantation as a therapy for hepatic dis-
ease, as determined by initial translational pilot studies
testing the direct hepatic administration of BM-derived
stem cells, have been encouraging and have suggested en-
hanced liver regeneration prior to partial hepatectomy
and improved liver function in advanced chronic liver dis-
ease [16-22]. Among the stem cells, mesenchymal stem
cells (MSCs) in particular have practical advantages in re-
generative medicine due to their high capability for self-
renewal, their potential for multipotent differentiation,
and their low immunogenicity. In addition, previous stud-
ies have demonstrated that bone marrow-derived mesen-
chymal stem cells (BM-MSCs) might be involved in the
regression of liver fibrosis [23,24].
Concomitantly, transforming growth factor (TGF)-β1
is a key mediator of fibrogenesis [25], and the TGF-β1
signaling pathway contributes to liver fibrosis progres-
sion [26]. More importantly, TGF-β1 mediates its bio-
logical functions via the canonical Smad pathway by
activating the transmembrane receptors that stimulate
the cytoplasmic Smad proteins, which in turn activate
collagen transcription [26,27]. Therefore, the TGF-β1-
activated Smad3 signaling pathway is critical for the
development of hepatic fibrosis, and TGF-β signaling
pathways are potential therapeutic targets for liver
fibrosis [27-29].
BM-MSCs can be easily harvested from bone marrow,
expanded ex vivo, and differentiated into many cell type
lineages, if desired. Because of their immunotolerance,
the establishment of MSCs as effective universal donor
cells [30] could then dramatically expand their thera-
peutic potential for cellular cardiomyoplasty. Despite
the initial hope that BM-MSCs could feature an im-
mune privilege, it is now increasingly recognized that
these cells trigger an immune reaction that leads to
their rejection in both allogeneic and xenogeneic set-
tings. In fact, a number of laboratories have recently re-
ported that MSCs may have a unique immunological
property capable of inducing tolerance in immunocom-
petent allotransplant or even xenotransplant recipients
[31]. The mechanisms of such immunotolerance have
been the subject of intense study, and three interrelated
candidate mechanisms are emerging [30,32]. MSCs ap-
pear to evade rejection by being hypoimmunogenic,
modulating T-cell phenotypes, and immunosuppressing
the local environment.
In this study, we investigated the effect of BM-MSCs
on hepatic fibrosis in a thioacetamide (TAA)-induced
cirrhotic rat model and the underlying mechanism by
which BM-MSCs ameliorate hepatic fibrosis.Methods
Preparation of human bone marrow-derived mesenchymal
stem cells
Human BM-MSCs were obtained from healthy persons
who voluntarily donated their bone marrow stem cells.
Approximately 10–20 mL of BM was aspirated from the
posterior iliac crests of humans under local anesthesia.
BM mononuclear cells were isolated through density-
gradient centrifugation (Histopaque-1077, Sigma-Aldrich,
St. Louis, MO, USA). Mononuclear cells (2–3 × 105 cells/
cm2) were plated in a 75-cm2 flask (Falcon, Franklin
Lakes, NJ, USA) with Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Grand Island, NY, USA) containing 10%
fetal bovine serum (FBS; Gibco) and 1% penicillin/
streptomycin (Gibco) and then cultured at 37°C in a 5%
CO2 atmosphere. When the cultures approached 80%
confluence, the cells were harvested by treatment with a
trypsin/EDTA solution (Gibco) and replated at a density
of 4–5 × 103 cells/cm2 in 175-cm2 flasks. Cells for injec-
tion were serially subcultured to passage four or five.
The human procedures and protocols were approved by
the Institutional Review Board (IRB) at Yonsei University
Wonju Severance Hospital (CR109021), and conducted
according to the principles of the Declaration of Helsinki.
All participants provided written informed consent prior
to participation in the study.
Immunophenotypes and differentiation assays of
BM-MSCs
The immunophenotypes of the BM-MSCs (CD14, CD34,
CD45, CD73, and CD105) were analyzed on the day of
injection, and their differentiation potentials were deter-
mined (osteogenesis and adipogenesis; Figure 1). For
the immunophenotype analysis, BM-MSCs were stained
with antibodies conjugated with fluorescein isothiocyanate
(FITC) or phycoerythrin (PE): CD14-FITC, CD34-FITC,
CD45-FITC, CD73-PE, and CD105-PE (BD Biosciences,
San Jose, CA, USA). Briefly, 5 × 105 cells were resus-
pended in 0.2 mL of phosphate-buffered saline (PBS) and
incubated with FITC- or PE-conjugated antibodies for
20 min at room temperature. FITC- or PE-conjugated
mouse IgGs were used as the control isotype at the same
concentration as the specific primary antibodies. The
fluorescence intensity of the cells was evaluated through
flow cytometry (Epics XL; Beckman Coulter, Miami, FL,
USA). Osteogenic differentiation was determined by first
plating the cells at 2 × 104 cells/cm2 in six-well plates and
then incubating them in the following osteogenic medium
for 2–3 weeks: DMEM medium supplemented with 10%
FBS, 10 mM β-glycerophosphate, 10−7 M dexamethasone,
and 0.2 mM ascorbic acid (Sigma-Aldrich) [33]. The
osteogenic differentiation was quantified from the re-
lease of p-nitrophenol from p-nitrophenyl phosphate by
the enzyme alkaline phosphatase [34]. For adipogenic
Figure 1 Immunophenotypes and differentiation potentials of the BM-MSCs. (A) The expressions of cell-surface antigens (CD14, CD34,
CD45, CD73, and CD105) were evaluated through flow cytometry. (B) BM-MSCs stained positively for endogenous alkaline phosphatase activity,
indicating osteogenic differentiation within an osteogenic medium (OM; I), or stained negatively in control medium (CM; II). BM-MSCs stained positively
for lipid droplets, indicating adipogenic differentiation within adipogenic medium (AM; III), or stained negatively in CM (IV) (Magnifications × 100).
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cm2 in six-well plates and cultured for 1 week; then, dif-
ferentiation was induced with adipogenic medium (10%
FBS, 1 μM dexamethasone, 0.5 mM 3-isobutyl-1-meth-
ylxanthine, 10 μg/mL insulin, and 100 μM indomethacin
in high-glucose DMEM) for an additional 3 weeks. The
differentiated cells were fixed in 4% paraformaldehyde
for 10 min and stained with fresh Oil Red-O solution
(Sigma-Aldrich) to display lipid droplets (Figure 1B).
The criteria regarding the use of MSCs included viability
greater than 80%; the absence of microbial contamination
(bacteria, fungus, virus, or mycoplasma) when tested 3–4
days before administration; CD73 and CD105 expression
in more than 90% of the cells; and the absence of CD14,
CD34, and CD45 in less than 3% of the cells, as assessed
by flow cytometry.
Induction of hepatic fibrosis and BM-MSC treatment in a
thioacetamide-induced cirrhotic rat model
Seven-week-old male Sprague–Dawley rats (Orient Bio
Inc.) were maintained at a room temperature of 25°C
with a 12/12-h light/dark cycle and with free access to
food and water throughout the 12-week experiment.
Hepatic fibrosis was induced in Sprague–Dawley rats by
intraperitoneal (i.p.) injections of TAA (Sigma, St. Louis,
MO, USA; 300 mg/kg body weight) twice a week for
12 weeks. The animals were randomly allocated into three
groups (each group, n =18) as follows: Group I (G1, shamgroup); Group II (G2, untreated cirrhotic group), which
received the TAA injection; and Group III (G3, BM-MSC
treated group), which received the TAA injection and the
BM-MSC treatment. The rats were anesthetized by intra-
muscular administration with a mixture of Zoletil® (Virbac
Laboratories, Carros, France) and Rompun® (Bayer Korea,
Seoul, Korea). With aseptic techniques, a 1-cm incision
was made caudal to the costal arch on the right flank to
expose the right lobe of the liver. With a syringe, 2 × 106
human BM-MSCs were injected directly into the right
lobe of the liver at 6 and 8 weeks during the 12-week TAA
administration in the BM-MSC treated group (Figure 2).
At 12 weeks, the animals were sacrificed after taking blood
samples, and liver tissue specimens were collected, fixed,
and immediately snap-frozen and stored at −80°C for ana-
lysis. The animal experimental procedures and protocols
were approved by the Institutional Animal Care and Use
Committee (IACUC) at Yonsei University Wonju College
of Medicine (YWC-131008-1).
Histomorphological and immunohistochemical analysis
Five-micrometer-thick sections of paraffin-embedded liver
tissues were prepared and stained with hematoxylin and
eosin (H&E), Masson’s trichrome (MTC), α-smooth muscle
actin (α-SMA), and Picrosirius Red. Fibrosis was evaluated
using the Laennec fibrosis scoring system (Table 1). In the
Laennec system, the thickness of the predominant type of
septae in each specimen is chosen, and the smallest nodule
Figure 2 Experimental design of BM-MSCs injection. Hepatic fibrosis was induced in Sprague–Dawley rats by intraperitoneal (i.p.) injections of
TAA (300 mg/kg) twice a week for 12 weeks. The BM-MSCs were injected directly into the right liver lobe twice, at 6 and 8 weeks during the
12-week TAA administration.
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to the clinical data evaluated fibrosis simultaneously and
prospectively. The Laennec fibrosis scoring system
was used because this system divides cirrhosis into
three subclasses, allowing for a more detailed estima-
tion of fibrosis after intervention [35]. In addition, to
estimate any treatment-induced changes in liver fibro-
sis, the fibrosis area was quantified as a percentage of
the total area that was positive for MTC stain in the
digital photomicrographs using a computerized image
analysis system (Analysis 3.0, Soft Imaging System,
Münster, Germany). To quantify the fibrosis area,
microscopic areas were selected randomly at an ori-
ginal magnification of 100X. For immunohistochemi-
cal analysis, the tissue sections were incubated with
primary antibody against α-SMA (diluted 1:800;
Neomarkers, Fremont, CA, USA) for 90 min at room
temperature after washing with buffer. The tissue sec-
tions were incubated with the chromogen 3-amino-9-
ethylcarbazole (BioGenex, San Ramon, CA, USA) for
5–7 min. Prior to mounting, the sections were coun-
terstained with hematoxylin and then dehydrated. An
UltraVision LP Large Volume Detection System (Lab
Vision, Runcorn, UK) was used as the detection sys-
tem. Morphological analysis of immunopositive cells
was also performed using a computerized image ana-
lysis system.Table 1 Laennec scoring system for staging fibrosis in liver sp
Stage Name Septa (thickness
and number)
Criteria
0 No definite fibrosis
1 Minimal fibrosis +/− No septa o
sinusoidal
2 Mild fibrosis + Occasional
3 Moderate fibrosis ++ Moderate t
4A Mild, definite, or probable cirrhosis +++ Marked sep
are thin (on
4B Moderate cirrhosis ++++ At least tw
biopsy leng
4C Severe cirrhosis +++++ At least on
composedPicrosirius Red staining was performed to quantify the
total amount of collagen. Five-micrometer-thick sections
of paraffin-embedded liver tissues were deparaffinized
and rehydrated with distilled water and stained with a
Picrosirius Red staining kit (Polysciences, Warrington,
PA, USA) according to the manufacturer’s instructions.
In addition, the amount of collagen (the main compo-
nent of fibrous tissue) was estimated from the collagen
proportionate area and expressed as the percentage of
the total area that was positive for Picrosirius Red stain
on microscopy (Olympus BX51, Tokyo, Japan) using a
computerized image analysis program (IMT i solution,
Vancouver, Canada). While measuring the collagen pro-
portionate area, we eliminated image artifacts and struc-
tural collagen in large portal tracts and blood vessel
walls [36].
Hepatocyte differentiation and identification of BM-MSCs
The expression of hepatocyte specific marker (Albumin)
was analyzed at 7 and 14 days after 2 × 106 human BM-
MSCs were injected directly into the right lobe of the liver
in TAA-induced hepatic fibrosis rats. Five-micrometer-
thick sections of liver tissues were incubated with human
anti-albumin antibody (A6684; Sigma) at 4°C overnight.
The slides were washed and incubated with Alexa Fluor®
488 (Invitrogen, Carlsbad, CA) secondary antibody for
1 hr in dark. The nuclei were stained with Hoechst.ecimens
Score
0
r rare thin septum; may have portal expansion or mild
fibrosis
1
thin septa; may have portal expansion or mild sinusoidal fibrosis 2
hin septa; up to incomplete cirrhosis 3
tation with rounded contours or visible nodules. Most septa
e broad septum allowed)
4
o broad septa, but not very broad septa and less than half of
th composed of minute nodules
5
e very broad septum or more than half of biopsy length
of minute nodules (micronodular cirrhosis)
6
Table 2 Primer sequences for quantitative PCR









GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGF-β1, transforming
growth factor-beta 1; collagen-1, type 1 collagen; α-SMA, α-smooth
muscle actin.
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confocal microscope (TCS SPE, Leica Microsystems
GmbH, Wetzlar, Germany). To identify injected BM-
MSCs in the hepatic fibrosis rat liver, BM-MSCs were la-
beled with fluorescent spherical silica nanoparticles with
CELL-STALKER™-CSR (Biterials) that contained Rhoda-
mine B isothiocyanate (RITC) according to manufac-
turer’s protocol. CELL-STALKER was centrifuged at
12,000 rpm for 10 min then supernatant was dis-
carded except pellet and sonicated for 5 min at 40
khz-300 w to evenly distribute particles, placed into
BM-MSCs culturing 75 T flask and incubated at 37°C
for 24 hrs. After incubation, the cells were harvested
by treatment with a trypsin/EDTA solution. The
2 × 106 BM-MSCs labeled with CELL-STALKER were
injected directly into the right lobe of the liver in
TAA-induced hepatic fibrosis rats and fluorescence
images for BM-MSCs were showed under a laser
scanning confocal microscope at 0, 3, 7, 14 days.
Biochemical analysis
Measurement of alanine transaminase (ALT), aspartate
transaminase (AST), total bilirubin, and albumin levels
were carried out using commercially available kits (Asan
Pharmaceutical, Republic of Korea) according to manu-
facturer’s instructions.
Quantitative real-time PCR analysis
Total RNA was isolated from liver tissues using TRIzol re-
agent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. RNA purity and concentration
were determined using a spectrophotometer (Ultrospec
2100 pro UV/Visible, Amersham Bioscience, Freiburg,
Germany). cDNA was synthesized from total RNA (1 μg)
using the GeneAmp RNA PCR Kit (Applied Biosystems,
Foster City, CA, USA) with oligo-dT (Applied Biosys-
tems). For the real-time polymerase chain reaction (PCR),
amplification was performed to measure the mRNA levels
of TGF-β1, type 1 collagen (collagen-1), and α-SMA using
sequence-specific primers (Table 2). Quantitative real-
time PCR using SYBR Green PCR Master Mix
(Applied Biosystems) was performed in an ABI
PRISM 7900HT Sequence Detection System (Applied
Biosystems) according to the manufacturer’s instruc-
tions. The data were analyzed using SDS 2.2.2 soft-
ware (Applied Biosystems). The cycle threshold (Ct)
values of the target genes were normalized to the Ct
values of the endogenous control (glyceraldehyde-3-
phosphate dehydrogenase). Relative changes were cal-
culated using the equation 2–ΔΔCt.
Hepatic hydroxyproline content
Liver tissues were hydrolyzed with 6 N HCl at 120°C
for 16 hrs. The hydrolysate was then cooled,neutralized with 6 N NaOH, and centrifuged at
13,000 g for 10 min. The supernatants were supple-
mented with 7% chloramine T, acetate/citrate buffer
(sodium acetate·3H2O, trisodium citrate·2H2O, citric
acid, with isopropanol). Ehrlich’s solution (dimethyla-
minobenzaldehyde with perchloric acid and isopropa-
nol) was then added and incubated at 60°C for
35min. After cooling, absorbance was measured at
560 nm with an Emax Precision Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA). Hydroxy-
proline concentration was calculated from a standard
curve prepared with hydroxyproline (Sigma, H5534).
The results were expressed as micrograms of hy-
droxyproline per gram of liver tissue.
Western blot assays
For total protein extracted from liver tissues, tissues were
homogenized using a TissueLyser II (QIAGEN GmbH,
Haan, Germany) with a tissue protein extraction reagent
(T-PER; Pierce, Rockford, IL, USA). The lysates were cen-
trifuged at 13,000 rpm for 15 min at 4°C, and the protein
concentrations of the supernatants were determined using
a protein assay kit (Bio-Rad Laboratories Inc., Hercules,
CA). Thirty micrograms of each liver protein was electro-
phoresed on a 10% sodium dodecyl sulfate-polyacrylamide
(SDS-PAGE) gel and then transferred to polyvinylidene
difluoride (PVDF) membranes (Millipore, Bedford, MA,
USA). The membranes were blocked with 5% skim milk
in Tris-Buffered Saline (TBS) containing 0.1% Tween-20
for 1 hr at room temperature, and the membranes were
then incubated with primary antibodies at 4°C overnight.
The primary antibodies were as follows: TGF-ß1 (Abcam,
Cambridge, MA, USA), α-SMA (Abcam), Smad3 (Cell
Signaling Technology, Danvers, MA, USA), and phospho
Smad3 (Cell Signaling Technology). Horseradish peroxid-
ase (HRP)-conjugated secondary antibodies against either
mouse IgG (Abcam) or rabbit IgG (Cell Signaling Tech-
nology) were incubated for 1 hr at room temperature.
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using an enhanced chemiluminescence (ECL) detection
kit (Amersham, Piscataway, NJ, USA). To normalize be-
tween experiments, the membranes were probed with a β-
actin antibody (Abcam), and the intensity of each protein
band was normalized to the intensity of β-actin.
Statistical analysis
The values are expressed as means ± standard deviations.
Nonparametric analysis was performed with the Kruskal-
Wallis H test. Statistical analysis was performed using
SPSS software version 20.0 (SPSS, Chicago, IL, USA). For
all tests, P values <0.01 were considered significant.
Results
Immunophenotypes and differentiation potentials of the
BM-MSCs
The immunophenotypes for CD14, CD34, CD45, CD73,
and CD105 cells were determined, and osteogenic or adi-
pogenic differentiation was induced on the day of BM-
MSC injection (Figure 1). In both the first and second
injected cell populations, CD73 or CD105 (which are posi-
tive markers of BM-MSCs) were expressed in more than
98% of the cells. However, CD14, CD34, and CD45 (which
are known to be negative markers of BM-MSCs) were
expressed in less than 1% of the cells (Figure 1). Therefore,
the BM-MSCs were differentiated into osteocytes and adi-
pocytes (Figure 1B).
Histological and immunohistochemical analysis
The Laennec fibrosis scoring system revealed detailed
individual changes within the cirrhotic tissue (F4A–F4C;
Table 1). Histological analysis was evaluated by H&E
and MTC staining (Figure 3). In the untreated cirrhotic
group, the liver sections were strongly stained by H&E
and MTC, showing definite cirrhosis (stage 4 fibrosis)
with regenerating nodules and fibrous septae (Figure 3A),
whereas the BM-MSC treated group showed mild fibro-
sis (Figure 3B). To compare these findings, the degree of
fibrosis was scored according to the Laennec fibrosis
scoring system. The BM-MSC treated group had a sig-
nificantly lower mean score than that of the untreated
cirrhotic group. According to the Laennec fibrosis sys-
tem, histologically, the BM-MSC treated group showed
significant improvement in hepatic fibrosis compared to
the untreated cirrhotic group (P <0.01). These results were
further confirmed by immunohistochemical staining reveal-
ing α-SMA expression and Picrosirius Red stain (Figure 3).
The relative expression of the collagen proportionate area
stained by Picrosirius Red was analyzed using an image
analysis program. The percentage of the collagen propor-
tionate area significantly decreased from 16.72 ± 5.51 to
5.06 ± 1.27 after BM-MSC treatment (P <0.01; Figure 3G).
In addition, the analysis of histopathological fibrosisscoring confirmed that cirrhosis was significantly re-
duced by BM-MSCs treatment, compared to the un-
treated cirrhotic group (Table 3).
Hepatocyte differentiation and identification of BM-MSCs
To investigated whether BM-MSCs are capable of undergo-
ing hepatic differentiation, the expression of albumin was
detected by immunofluorescence staining. At 7 days after
BM-MSCs injection, expression of albumin was weakly de-
tected. However, intensity of albumin staining was stronger
at 14 days (Figure 4).
To identify injected BM-MSCs to the hepatic fibrosis
rat liver, fluorescence red labeled BM-MSCs were showed
at 0, 3, 7, 14 days after direct injection in hepatic fibrosis
rat liver. Fluorescence intensity from labeled BM-MSCs
was maintained for 14 days in liver tissue. However fluor-
escence intensity from labeled BM-MSCs was gradually
reduced and disappeared at 14 days (Additional file 1:
Figure S1).
Differentiation of BM-MSCs into hepatocytes was de-
termined by immunofluorescence staining using albumin
antibody and identification of BM-MSCs in hepatic fibro-
sis was determined by fluorescent microscopy using CELL
STALKER-CSR dye staining. Consequently, we showed
that fluorescence intensity from labeled BM-MSCs with
CELL-STALKER was gradually disappeared and albumin-
stained areas had gradually expanded at 14 days after in-
jection, considering that BM-MSCs had transdifferentiated
into hepatocytes after injection. Based on these results, it
may suggested that BM-MSCs had transdifferentiated into
hepatocytes after injecting hepatic fibrosis rats.
Biochemical analysis
The serum levels of ALT, AST, and total bilirubin were
significantly decreased in BM-MSCs treated group. In
addition, serum level of albumin in the BM-MSC treated
group were increased compared to the untreated cir-
rhotic group (P <0.01; Figure 5).
TGF-β1, collagen-1, and α-SMA mRNA levels
After BM-MSC administration, the mRNA relative ex-
pression levels of TGF-β1, collagen-1, and α-SMA
were determined through quantitative real-time reverse
transcription-PCR (RT-PCR) analysis. The collagen-1
mRNA relative expression levels were 1 ± 0.39, 14.04 ±
4.54, and 4.74 ± 2.46 (P <0.01) in G1, G2, and G3,
respectively (Figure 6B). In addition, the TGF-β1 and
α-SMA mRNA relative expression levels were 1 ± 0.27,
4.61 ± 0.61, and 2.14 ± 0.35 (P <0.01) and 1 ± 0.32, 8.83
± 3.12, and 2.62 ± 0.41 (P <0.01) in G1, G2, and G3, re-
spectively (Figure 6A, 6C). The TGF-β1, collagen-1, and
α-SMA mRNA relative expression levels in the BM-
MSC treated group were significantly decreased com-
pared to the untreated cirrhotic group (P <0.01).
Figure 3 Histological analysis and the relative expression of the collagen proportionate area. Histological analysis was evaluated by MTC
(A, B), α-SMA (C, D), and Picrosirius Red staining (E, F). BM-MSC treatment induced an improvement of cirrhosis from F4C (A, C, E) to F4A
(B, D, F) according to the Laennec fibrosis scoring system. Untreated cirrhotic group (A, C) show cirrhosis with at least one broad septum with
minute nodules (F4C) and BM-MSC treated group (B, D) show cirrhosis with marked septation with rounded contours or visible large nodules
(F4A). Picrosirius Red staining of a section from a liver biopsy specimen showed a change in collagen proportion stained as red from untreated
cirrhotic group (E) to BM-MSC treated group (F). The relative area of collagen stained by Picrosirius Red was analyzed with an image analysis
program (G). The percentage of the collagen proportionate area decreased from 16.72 ± 5.51 to 5.06 ± 1.27 after BM-MSC treatment (P <0.01).
(Magnifications × 100). Values are expressed as means ± SD. *P <0.01.
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Table 3 Histological stage of hepatic fibrosis
Group Stage 0 Stage 1 Stage 2 Stage 3 Stage 4A Stage 4B Stage 4C Average
Score 0 1 2 3 4 5 6
G1 18 0
G2 2 7 9 5.4
G3 2 7 6 3 3.6
Group I (G1, sham group); Group II (G2, untreated cirrhotic group); Group III (G3, BM-MSC treated group).
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The content of hepatic hydroxyproline was quantified
colorimetrically from liver tissues. Quantitative analysis
showed that the contents of hepatic hydroxyproline of
the liver tissue were 16.44 ± 4.07, 85.81 ± 17.62, and
46.25 ± 13.19 (P <0.01) in G1, G2, and G3, respectively
(Figure 6D). The content of hepatic hydroxyproline was
significantly lower in the BM-MSC treated group than in
the untreated cirrhotic group.TGF-β1 and α-SMA protein expression levels
The TGF-β1 and α-SMA protein expression levels were
measured through western blot assays (Figure 7). The
TGF-β1 and α-SMA protein expression levels were 1 ±
0.15, 2.5 ± 0.39, and 1.41 ± 0.41 (P <0.01) and 1 ± 0.14,
1.8 ± 0.49, and 1.16 ± 0.25 (P <0.01) in G1, G2, and G3,
respectively (Figure 7). The TGF-β1 and α-SMA protein
expression levels in the BM-MSC treated group were sig-
nificantly decreased compared to the untreated cirrhotic
group (P <0.01).Figure 4 Immunofluorescence staining for albumin expression after B
image showed BM-MSCs with hepatocyte differentiation and albumin expr
confocal microscope. Merged immunofluorescence images of albumin (greWe examined the effect of BM-MSCs on the status of
Smad3 and found that Smad3 phosphorylation was mark-
edly increased in the untreated cirrhotic group but was
significantly decreased after BM-MSC treatment. These
results demonstrate that BM-MSCs modulated the TGF-
β1/Smad signaling pathway by attenuating TGF-β1 and
Smad3 expression and inhibiting Smad3 phosphorylation.
Discussion
In this study, we investigated the effect of BM-MSCs on
hepatic fibrosis in a TAA-induced cirrhotic rat model
and explained the fundamental mechanism of hepatic
fibrosis attenuation caused by BM-MSC treatment. The
major findings of our study are as follows: (1) administra-
tion of MSCs at 2 × 106 cells into TAA-induced cirrhotic
rat livers via direct injection allowed recovery from TAA-
induced fibrosis at 4 weeks after BM-MSC treatment; (2)
BM-MSCs recovered liver function through decreases in
TGF-β1, collagen-1, and α-SMA expression; and (3) BM-
MSCs led to the recovery of liver function via the TGF-
β1/Smad signaling pathway.M-MSCs injection by confocal microscope. Immunofluorescence
ession at 7 days (A) and 14 days (B) after BM-MSCs injection under a
en) and hoechst (blue). (Scale bar, 100 μm).
Figure 5 Effect of BM-MSCs on serum biomarkers. (A) Alanine aminotransferase (ALT), (B) aspartate aminotransferase (AST), (C) total bilirubin,
and (D) albumin after injection of BM-MSCs. Values are expressed as means ± SD. *P <0.01.
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http://www.biomedcentral.com/1471-230X/14/198Recently, stem cell-based therapy has been proposed
as a promising alternative approach for end-stage liver
diseases. Stem cell therapies have shown promising bene-
fits for hepatic fibrosis in experimental and clinical studies
[11,12,17,20]. BM consists of two main populations of
stem cells, hematopoietic stem cells and MSCs, the latterFigure 6 TGF-β1, collagen-1, and α-SMA mRNA levels and measureme
the mRNA relative expression levels of TGF-β1 (A), collagen-1 (B), and α-SM
1 ± 0.27, 4.61 ± 0.61, and 2.14 ± 0.35 (P <0.01) and 1 ± 0.39, 14.04 ± 4.54, and
in G1, G2, and G3, respectively. (D) Measurement of hepatic hydroxyproline
analysis showed that the contents of hepatic hydroxyproline of the liver tis
G2, and G3, respectively. Values are expressed as means ± SD. *P <0.01.of which have been considered as alternative cell sources
for liver or hepatocyte transplantation [22]. In liver dam-
age, MSCs differentiate into hepatocytes, stimulate the re-
generation of endogenous parenchymal cells, migrate to
damaged sites, and enhance fibrous matrix degradation
(antifibrotic effects). A recent study suggested that MSCsnt of hepatic hydroxyproline content. After BM-MSC administration,
A (C) through quantitative real-time PCR were significantly decreased
4.74 ± 2.46 (P <0.01) and 1 ± 0.32, 8.83 ± 3.12, and 2.62 ± 0.41 (P <0.01)
content was quantified colorimetrically from liver tissues. Quantitative
sue were 16.44 ± 4.07, 85.81 ± 17.62, and 46.25 ± 13.19 (P <0.01) in G1,
Figure 7 TGF-β1, α-SMA, and Smad3 protein expression levels. After BM-MSC administration, the TGF-β1 (A, C) and α-SMA (A, D) protein
expression levels through western blot assays were significantly decreased 1 ± 0.15, 2.5 ± 0.39, and 1.41 ± 0.41 (P <0.01) and 1 ± 0.14, 1.8 ± 0.49,
and 1.16 ± 0.25 (P <0.01) in G1, G2 and G3, respectively. (B) Phosphorylation of Smad3 was assessed through western blot assays. Values are
expressed as means ± SD. *P <0.01.
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http://www.biomedcentral.com/1471-230X/14/198have antifibrotic effects on the injured liver in animal
models of liver fibrosis [37]. Consistent with these results,
we showed that the administration of BM-MSCs amelio-
rated hepatic fibrosis.
TAA-induced cirrhosis is a well-known classical experi-
mental cirrhosis model [38,39]. In our study, we con-
firmed that TAA administration resulted in deficiencies in
liver function and a progressive increase in collagen ac-
cumulation in the liver with periportal cirrhosis charac-
terized by portal-portal fibrous septa surrounding the
hepatic lobules.
Cirrhosis and advanced fibrosis are generally consid-
ered irreversible conditions, even after the removal of
the hepatic injury. Through histological H&E and MTC,
and α-SMA staining, we showed that BM-MSC adminis-
tration resulted in significant improvement of hepatic fi-
brosis compared to the untreated cirrhotic group. There
was a clear histological variability of severity within cir-
rhosis classified as F4 by the METAVIR system. Cirrho-
sis is currently considered potentially reversible if the
cause of the injury is removed. The lack of subclassifica-
tion within cirrhosis can be problematic when assessing
the antifibrotic effect of agents such as antiviral drugs.
For instance, even though antifibrotic therapy leads to
the improvement of hepatic fibrosis from F4C to F4A in
the Laennec system, the lack of change under the conven-
tional METAVIR system may lead to the false conclusion
that treatment is ineffective. Hence, further histological
subclassification of cirrhosis is required [4,35]. In this
study, we applied the new Laennec fibrosis scoring system
to provide a more detailed classification of F4 cirrhosis.According to this scoring system, histological improve-
ment was observed in hepatic fibrosis after BM-MSC
treatment (P <0.01). These results were confirmed by im-
munohistochemical assays revealing α-SMA expression
and Picrosirius Red staining. In addition, the percentage
of the collagen proportionate area and the content of hep-
atic hydroxyproline significantly decreased after BM-MSC
treatment. These results indicated that BM-MSCs im-
proved liver structure in TAA-induced cirrhotic rats.
TGF-β1 is a primary mediator particularly in liver
fibrogenesis. TGF-β1 promotes HSCs to transition into
MFBs; it also stimulates the synthesis of ECM factors
such as collagen-1 and inhibits its degradation [40]. Fur-
thermore, the expression of α-SMA in the liver is an in-
dicator of HSC activation, which is recognized as a key
player in hepatic fibrosis and cirrhosis [41]. Likewise,
this study showed that BM-MSCs recovered liver func-
tion, as indicated by decreased TGF-β1, collagen-1, and
α-SMA gene expression. Furthermore, α-SMA protein
expression significantly decreased after BM-MSC treat-
ment. The results of our study are in agreement with
those of Campbell JS et al. [42]. Indeed, the activation of
TGF-β/Smad signaling is a key mechanism of liver fi-
brosis in both experimental and human chronic liver
diseases [43]. We also showed P-Smad3/Smad3, down-
stream effectors of the TGF-β1 signaling pathway, and
found that MSC transplantation inhibited Smad3 phos-
phorylation. Hence, this study has confirmed a signifi-
cant inhibitory effect of BM-MSCs on TAA-induced
cirrhosis in rats, which likely correlates with the TGF-
β1/Smad signaling pathways.
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In conclusion, our study showed that BM-MSC treat-
ment inhibited fibrosis formation and the progression of
TAA-induced cirrhosis in rats by modulating the TGF-
β/Smad signaling pathway. Therefore, BM-MSC therapy
leads to the improvement of hepatic fibrosis and may pro-
vide a new strategy for antifibrosis therapy in the future.
Additional file
Additional file 1: Figure S1. Fluorescence images of injected BM-MSCs
labeled with CELL-STALKER in hepatic fibrosis rat. BM-MSCs labeled with
fluorescence red were showed at 0 (A), 3 (B), 7 (C), 14 (D) days after direct
injection in hepatic fibrosis rats (CELL STALKER-CSR dye staining, red: Scar
bar, 100 μm).
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